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Infected erythrocyte-derived extracellular vesicles
alter vascular function via regulatory Ago2-miRNA
complexes in malaria
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Malaria remains one of the greatest public health challenges worldwide, particularly in
sub-Saharan Africa. The clinical outcome of individuals infected with Plasmodium falciparum
parasites depends on many factors including host systemic inflammatory responses, parasite
sequestration in tissues and vascular dysfunction. Production of pro-inflammatory cytokines
and chemokines promotes endothelial activation as well as recruitment and infiltration of
inflammatory cells, which in turn triggers further endothelial cell activation and parasite
sequestration. Inflammatory responses are triggered in part by bioactive parasite products
such as hemozoin and infected red blood cell-derived extracellular vesicles (iRBC-derived
EVs). Here we demonstrate that such EVs contain functional miRNA-Argonaute 2 complexes
that are derived from the host RBC. Moreover, we show that EVs are efficiently internalized by
endothelial cells, where the miRNA-Argonaute 2 complexes modulate target gene expression
and barrier properties. Altogether, these findings provide a mechanistic link between EVs and
vascular dysfunction during malaria infection.
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D
espite continuing efforts, malaria remains a major
public health threat worldwide. Although the majority
of infections remain asymptomatic or uncomplicated,
a small proportion of infected people develops severe symptoms
and may die. The most virulent malaria parasite, P. falciparum
causes B650,000 deaths annually, most of them amongst
children below the age of 5 in sub-Saharan Africa1. The factors
that regulate the transition from an uncomplicated disease to
serious conditions including cerebral malaria (CM) and severe
malarial anaemia are poorly understood. Even when treated CM
has a poor prognosis with fatality rates of 30–50%, and survivors
often suffer from neurological complications.
The pathology of P. falciparum malaria is related to the
capability of parasite-infected red blood cells (iRBCs) to sequester
in deep tissues by adherence to the microvasculature. For this
purpose the parasite expresses a variant surface antigen,
P. falciparum erythrocyte membrane protein 1 (PfEMP1). Each
P. falciparum parasite genome encodes about 60 PfEMP1 variants
that enable the parasite to attach iRBCs to different host receptors
on the vascular lining of various tissues, including brain and
placenta2. Sequestration prevents splenic clearance of mature
iRBCs and contributes to pathology by reducing blood flow and
promoting inflammation in the capillaries. Inflammatory
cytokines can induce receptor expression on the surface of the
endothelium, thereby enhancing iRBC binding. In addition,
adhesion of iRBCs to the endothelium can increase vascular
permeability and apoptosis of the endothelial cells3. Indeed,
vascular dysfunction is a common feature of cerebral malaria
through destruction of the blood–brain barrier and the formation
of haemorrhages4–6. Interestingly, in vitro experiments have
demonstrated that increased vascular permeability does not only
require direct iRBC interactions but can also be caused by soluble
factors released by iRBCs7. Transfer of released malaria antigens
to endothelial cells has also been observed in autopsy studies in
the context of acute inflammatory lesions in cerebral tissue5,8.
Likewise tissue surveys in autopsy studies have detected parasite
markers in endothelial cells of multiple tissues9. Antigen transfer
from iRBCs to brain endothelial cells appears to occur via
membranous structures during transient iRBC—endothelial cell
interactions7, a process reminiscent of trogocytosis.
Release of membranous material in the form of extracellular
vesicles (EVs) from iRBCs during parasite development has
initially been described in the rodent malaria model and more
recently in P. falciparum10–13. EVs are small vesicles released by
almost all eukaryotic cell types. EVs derived from iRBCs are
increased in serum of malaria patients, in particular during severe
disease14. EVs can activate cells of the innate immune system in
the rodent malaria system and in human malaria11,13. We have
recently demonstrated that EVs can also facilitate cellular
communication between iRBCs by transferring signalling
molecules from a donor to a recipient iRBC. Moreover this
communication pathway is linked to the formation of malaria
transmission stages11 and capable of transferring (episomal)
DNA10.
Compositional analysis of EVs derived from iRBCs identified a
specific set of RBC and parasite proteins as well as RNA species
including small RNA species11. In other systems, EVs have been
shown to contain nucleic acids, in particular messenger RNA
(mRNA) and microRNA (miRNA) that can be transferred to and
function in recipient cells. For example, Epstein-Barr virus
induces secretion of EVs that contain viral miRNAs from infected
cells, and these secreted viral miRNAs can downregulate cytokine
expression in uninfected monocyte-derived dendritic cells15.
Similarly, hepatitis C virus induces secretion of exosomes from
infected hepatocytes that are also able to transmit the virus to
naive cells16. Importantly, extracellular miRNAs in complex with
proteins and lipids are very stable and protected from
degradation by RNAses and are therefore particularly well
suited to transduce signals17. miRNAs are 19–24-nucleotide
noncoding RNAs that are derived from larger primary transcripts
encoded in the genome. Following initial processing by the
RNases Drosha and DGCR8 in the nucleus, the pre-miRNA is
exported to the cytoplasm where it is processed to a miRNA
duplex by another RNase termed Dicer18. One of the RNA
strands is loaded and incorporated into the effector protein
Argonaute 2 (Ago2) to form the RNA-induced silencing complex
(RISC)19. The sequence-specific miRNA guides the RISC complex
either to target sites in coding regions of target mRNAs for
endonucleolytic cleavage or to the 30-untranslated regions (UTRs)
leading to translational repression20. The latter can occur through
a variety of reported mechanisms including decreased mRNA
stability due to deadenylation and uncapping, or via direct
inhibition of translation21.
In this study, we tested the hypothesis that iRBC-derived EVs
contain miRNAs that can modulate target genes in recipient cells.
We identified multiple miRNA species in EVs, and we
demonstrated that they are bound to Ago2 and form functional
complexes. Furthermore, we observed transfer of iRBC-derived
EVs into endothelial cells, repression of miRNA target genes and
alteration of endothelial barrier properties.
Results
iRBC-derived EVs contain a subset of human miRNAs. We
have previously developed a protocol for purification of iRBC-
derived EVs, and we have demonstrated the presence of specific
parasite and host proteins in purified EVs, including human
Ago2. Initial experiments also demonstrated that EVs from iRBCs
contain RNA, although the nature of these RNA species remained
unclear11. To further confirm these initial findings and investigate
the composition of nucleic acids in EVs, we prepared purified
EVs from iRBC cultures and analysed the size distribution of
RNA by the Agilent 2100 bioanalyzer (Fig. 1a). Starting with 1mg
of purified EVs we extracted total RNA. For this purpose EVs
were pretreated with RNase A before lysis in order to remove
potential contaminating free RNA bound to EVs or co-purified
during the isolation process. We also excluded possible serum
contamination by pre-clearing the serum of host EVs with
ultracentrifugation before culturing the parasites. Analysis by
bioanalyser failed to detect RNA species above 150 nucleotides in
size, including the diagnostic ribosomal RNA bands
(Supplementary Fig. 1a). In contrast we detected small RNA
species in the range of 21–25 nucleotides suggesting the presence
of mature miRNAs (Fig. 1a). Since Plasmodium parasites lack
functional RNA interference machinery capable of producing
miRNAs22, we hypothesized that these miRNA were host-
derived. Indeed it has previously been shown that human RBCs
express a small set of miRNA species during maturation, with
various roles during RBC development23. To profile the
composition of human miRNAs in EVs from iRBCs, we used a
nanostring expression array comprising probes for all 800 human
miRNA species. Specifically, we compared the composition and
amount of human miRNAs from uninfected RBCs, infected RBCs
and EVs. As expected, we detected RBC-specific miRNAs in all
four preparations with a total of 21 miRNAs specifically present
in RBCs and a small subset of those in iRBCs and EVs from
iRBCs (Fig. 1b and Supplementary Data 1). However, except for
miR-451a and let-7b, all the miRNA species were depleted in
iRBC and EV samples as compared with uninfected RBCs
(Fig. 1c). Notably, miR-451a is the most abundant miRNA in
RBCs and plays an important role in erythroid homoeostasis
during RBC development24. To independently confirm presence
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of mature miRNA species in RBCs, iRBCs and EVs, we performed
northern blots for miR-451a, let-7b, RNU6 and miR-106b (Fig. 1d).
All four miRNA species were detected in RBCs and EVs prepared
from iRBCs culture supernatants. Altogether these data demonstrate
the presence of a subset of RBC-specific miRNAs, notably the RBC-
specific miR-451a species, in EVs and iRBCs.
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Figure 1 | Detection of human miRNA species in EVs. (a) EVs derived from iRBCs contain small RNAs. RNA samples were prepared from EVs and
analysed by Agilent Bioanalyzer Small RNA Chip. Small RNA species of up to 150 nucleotides are detected, including species between 20 to 25 nucleotides
(range marked by green lines). FU, fluorescence units. (b) miRNA profiling of iRBCs, EVs from iRBCs and RBCs by nanostring. miRNA preparations from
four experiments were analysed using a Nanostring miRNA array containing 800 human miRNA species. Normalized data from the entire array are shown
in the left panel. Twenty-one miRNAs are expressed in RBCs, of which a subset is also present in iRBCs and EVs from iRBCs (right). These are (in order of
expression levels) miR-451a, let-7b, let-7a, miR-106b and miR-15b. Those that are further characterized in this study are marked with black arrows.
(c) Differential abundance of miRNA species in RBCs, EVs from iRBCs and RBCs. The normalized Nanostring data from b are represented as correlations
between the mean expression across four experiments of RBC and the mean expression of either iRBCs (black boxes) or EVs from iRBCs (grey diamonds).
miR-451a and let-7b show similar abundance across all three populations, while the other miRNA species are greatly reduced in iRBCs and EVs from iRBCs.
(d) Detection of miRNAs by northern blot. RNA samples from RBCs and EVs from iRBCs are hybridized with probes specific for miR-451a, let-7b and
miR-106b. The northern blot shows specific bands at the expected size of 22 nucleotides for miR-451a and let-7b, and of 21 nucleotides for miR-106b. In
addition unprocessed Pre-miRNA species at the expected size of 70 nucleotides are detectable for let-7b and miR-106b. Shown is also a blot for U6 small
nuclear RNA (RNU6) as a control for RBC-derived non-miRNA RNA species23. Samples were normalized using equal RNA input.
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Mature RBCs and iRBCs contain human Ago2 protein. There
is increasing evidence for the EV-mediated transfer of miRNAs
between cells. Although generally subject to degradation by
nucleases, mature miRNAs are protected and functional when
bound to Ago2 (ref. 25). We therefore hypothesized that the
miRNA detected in iRBCs and EVs may be bound to Ago2.
Functionality of RNAi has been described in erythroid cells26, but
there is no evidence so far that the machinery remains functional
once erythroid cells mature to normocytes (that is, mature RBCs).
To investigate whether functional miRNAs may be present in
mature RBCs, we first monitored expression of components of
the RNAi machinery during in vitro RBC maturation from
hematopoietic stem cells to normocytes27. We detected Ago2 in
mature RBCs, while Drosha and Dicer were only detectable in
erythroid cells, before their enucleation and maturation into
reticulocytes (Fig. 2a). To determine the localization of Ago2 in
mature RBCs, we performed immunofluorescence assays (IFA)
and flow cytometry using specific antibodies to human Ago2. In
normocytes, Ago2 was primarily localized to the cell periphery,
close to the RBC membrane (Fig. 2b). Analysis of infected RBCs
demonstrated a similar localization pattern in RBCs containing
young ring stage parasites (up to B20 h post invasion). Later
during development, however, the signal was progressively lost
(Fig. 2b,c). We have previously observed a similar dynamic in
subcellular localization for the RBC lipid raft protein stomatin,
with stomatin disappearance coinciding with the peak of EV
release from iRBCs during late schizont maturation11. We further
characterized the subcellular localization of Ago2 during
iRBC development by sequential permeabilization using the
pore-forming agents tetanolysin and saponin. Tetanolysin forms
pores in the RBC membrane but leaves the internal membranes
intact, while saponin also permeabilizes the parasitophorous
vacuole membrane while leaving the parasite intact28(Fig. 2d).
Sequential treatment of iRBCs with tetanolysin and saponin
results in a RBC cytosol, a parasitophorous vacuole and a parasite
and host membrane fraction (pellet). Western blot analysis
demonstrated Ago2 presence in the soluble fractions representing
RBC cytosol and parasitophorous vacuole. During the first 24 h of
parasite development, the protein was also present in the pellet
fraction, confirming the observed IFA localization in the parasite
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Figure 2 | Detection of human Ago2 in RBCs and iRBCs. (a) Expression of RNAi machinery during RBC development. Cell lysates from different
developmental stages of erythropoiesis were prepared (day 11: basophilic and polychromatic erythroblasts, day 18: orthochromatic erythroblasts and
reticulocytes, day 21: reticulocytes and normocytes; representative images are shown). Ago2 is detectable in mature RBCs while dicer, drosha (and human
histone H3) are not present. Stomatin is present in all preparations. (b) IFA of Ago2 in RBCs and iRBCs. Ago2 is localized to the RBC periphery in uninfected
and infected RBCs, however, labelling is reduced in later parasite stages. Notably, ring stage parasites also show Ago2 accumulation in the parasite. Scale
bar; 1mm. (c) Flow cytometry analysis of Ago2 labelling in RBCs and iRBCs. Uninfected RBCs and iRBCs were gated based on SYBR staining (nuclear
content, n) and Ago2 labelling. Young iRBCs (rings, and trophozoites with n¼ 1) show the highest Ago2 labelling, confirming IFA data. (d) Sequential
fractionation of purified infected parasites analysed by western blot. iRBC samples were collected at four time points post invasion, separated from
uninfected RBCs and fractionated. The host cytosol was released with 1 HU of tetanolysin (TTL) and subsequently the PV contents were released with
0.035% of saponin (SAP). The pellet contains parasite material and host membranes while the TTL supernatant contains RBC cytosol and the SAP
supernatant contains soluble parasitophorous vacuole material. The parasitophorous vacuole membrane marker PfExp-1 and parasite nuclear histone H3
are detectable in the pellet fraction across the asexual parasite cycle. Ago2 is present in cytosol (SAP, TTL) across the cycle but only present in the pellet
fraction in early parasite stages, supporting the dynamic distribution observed by IFA. Host stomatin is present in cytosol (SAp, TTL) and membranes
(pellet) throughout the cycle. Data are representative of three independent experiments. pi: post invasion.
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and at peripheral RBC membranes and/or cytoskeleton. At later
time points, the protein could not be detected in the pellet
anymore, suggesting relocalization or secretion, possibly via EVs.
Ago2 and miRNA are found inside EVs. Indeed, we detected
Ago2 (and stomatin) in EV preparations from iRBCs by western
blot analysis (Fig. 3a), corroborating our previous proteomics
data11. We independently confirmed that Ago2 is present within
EVs by immune EM with specific anti-Ago2 antibodies using
purified EVs (Fig. 3b). Previous work has demonstrated that most
of the miRNAs found in the plasma of healthy donors are mainly
associated with proteolipid complexes and not with EVs29. To
exclude the possibility that Ago2 and miRNA molecules originate
from protein–lipid complexes present in the serum, we used two
complementary approaches, as recently described29. First, we
performed size exclusion chromatography and demonstrated that
human serum indeed contains a subpopulation of miRNAs
(and proteins) that elute in the same fractions as those from EV
preparations. Importantly, EV preparations do not elute miRNA
or protein in the major serum fractions, demonstrating that our
EV samples are devoid of serum contaminants (Fig. 3c,d).
Second, Proteinase K protection assays with EV preparations
demonstrated that Ago2 and miRNA molecules (and stomatin
control) were protease resistant while the surface exposed
Glycophorin C was sensitive (Fig. 3e,f), as we have shown
previously11. Altogether these experiments demonstrate that
Ago2 and miRNA molecules are present within EVs.
miRNAs form a functional RISC complex with Ago2 in EVs.
miRNAs form a stable silencing complex with Ago2 (that is, the
RISC complex) in order to be functional. RISC binds to the tar-
geted mRNA through the seeding sequence of the miRNA.
Having established presence of both specific miRNA species and
Ago2 in EVs we next wanted to determine whether they formed a
functional silencing complex. To test sequence-specific endonu-
cleolytic activity of RISC we incubated purified EV lysates from
infected RBCs with a radio-labelled RNA sensor probe containing
a complementary sequence to either miR-451a or let-7b. This
R
el
at
iv
e 
ex
pr
es
sio
n
(fo
ld 
ind
uc
tio
n)
6 8 10 12 14 16 18 20 22
0
50
100
150
miR-451a
let-7a
Fraction number
6 8 10 12 14 16 18 20 22
0
50
100
150
miR-451a
let-7a
Fraction number
R
el
at
iv
e 
ex
pr
es
sio
n
(fo
ld 
ind
uc
tio
n)
Ago2
GlyC
Stomatin
0 60453015
Min
Proteinase K
(5 mg ml–1) – + + + + miR-451a
0 15 30 45 60
0.0
0.5
1.0
Min
let-7a
0 15 30 45 60
0.0
0.5
1.0
Proteinase K
Control
Proteinase K
Control
Min
R
el
at
iv
e 
ex
pr
es
sio
n
(fo
ld 
ind
uc
tio
n)
R
el
at
iv
e 
ex
pr
es
sio
n
(fo
ld 
ind
uc
tio
n)
Ago2
Stomatin
SerumEVs
R
BC
EV
1
EV
2
EV
3
A2
80
 (p
rot
ein
, p
erc
en
tag
e)
6 8 10 12 14 16 18 20 22 24
0
20
40
60
80
100 BSA
EVs
Serum
Tyr
Fraction number
97
37
31
a b c
d
e f
Figure 3 | Ago2 and miRNA are present within purified EVs. (a) Expression of Ago2 and stomatin in multiple EV preparations was probed by western
blot. (b) Immuno electron microscopy. EVs were prepared and processed as described in materials and methods for labelling with human Ago2 antibody.
The field of view shows multiple EVs with internal immunogold labelling, demonstrating that Ago2 is present in EVs rather than associated by surface
attachment. Inserts: three representative EVs in higher magnification (scale bar, 100 nm). (c) Elution profile of purified EVs, human serum, BSA and tyrosine
(Tyr) after size-exclusion separation. Protein abundance was determined by absorbance at 280 nm. Points represent the mean±s.d. of three experiments
performed in triplicate. (d) Fractions from purified EVs (left) and serum (right) were assayed for miR451a (black) and let-7a (red) using absolute
quantification by TaqMan qPCR. The mean±s.d. of one representative experiment is shown (n¼ 2). (e,f) The Ago2-miRNA complexes are protected from
protease K digestion. (e) EVs were treated with proteinase K (5mgml 1, or untreated control) at 55 C. At times indicated, aliquots were removed and
assessed for Ago2, stomatin and Glycophorin C expression by western Blot. In contrast to Glycophorin C, Ago2 and stomatin were protected from digestion
by proteinase K. (f) Untreated (open symbols) or treated samples (close symbols) were also analysed for miR-451a and let-7a expression by qPCR. Points
represent miRNA copies detected at each time relative to the control sample at time point 0. The mean±s.d. of one representative experiment is shown
(n¼ 3). qPCR, quantitative PCR.
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initial experiment demonstrated
time-dependent cleavage activity starting at 30min of incubation
time (Fig. 4a). Next, we titrated the activity of EV lysate,
demonstrating a window of specific cleavage of the miR-451a
probe at 0.04 to 0.65mgml 1 of input lysate. At higher
concentrations the probe is fully degraded, suggesting presence of
nonspecific RNases in the EV lysate (Fig. 4b). Importantly,
pre-treatment of EV lysate with either Proteinase K (to degrade
proteins) or the Mg2þ chelator EDTA (to block enzymatic
activity) inhibited the cleavage reaction, demonstrating
requirement of active enzyme (Fig. 4c,d). We also demonstrated
specificity of the endonucleolytic cleavage reaction, as a probe
with mutated cleavage site was not processed when incubated
with EV lysate (Fig. 4e). To further confirm the functionality of
the RISC complex contained in EVs, we transiently transfected
HEK293 cells with a reporter gene construct. In fact, the
luciferase-based assay with miR-451a target sequence in the
30-UTR of a reporter cassette demonstrated significant
downregulation of the reporter gene activity in transfected
HEK293 cells upon co-incubation with EVs (Fig. 4f). In contrast,
we did not detect significant reporter downregulation when
placing other miRNA target sequences in the 30-UTR such as
let-7b or miR-106a (Supplementary Fig. 1c). Indeed, the addition
of a let-7b, miR-15a of miR-106a responsive element significantly
decreased the activity of the luciferase reporter gene, even in the
absence of EVs, indicating that HEK cells express a significant
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EDTA (d) inhibits the cleavage reaction, while a DMSO control remains unaffected. (e) Disruption of the miR-451a cleavage site on the probe (Mut) blocks
processing, while the wild-type probe (WT) is efficiently cleaved. (f) 30-UTR degradation activity. HEK293 cells transiently expressing a Renilla luciferase
reporter gene with binding site complementary to miR-451a in the 30-UTR of the reporter cassette were incubated with EVs derived from iRBCs for 48 h
prior to luciferase activity measurements. Results are normalized based on constitutive Firefly luciferase activity, and expressed as mean (±s.e.m.)
percentage of control (n¼ 3 experiments). P versus control (Student’s t-test). (g,h) Activity of purified Ago2-miRNA complex. (g) Quantification of miRNA
by qRT-PCR. Protein extracts derived from purified EVs were subjected to immunoprecipitation (IP) using anti-Ago2 antibody, followed by miR-451a
quantification using qRT-PCR. Results are normalized by the 2-Ct method, using the RNU6 gene as a reference and expressed as the enrichment versus the
IgG1 negative control (mean± s.e.m.; n¼4 experiments). P versus control (Student’s t-test). (h) Detection of miRNA by northern blot. Negative control
represents IP using control IgG. (i) Activity of Ago2-miRNA complex. The precipitated complex was incubated with a miR-451a probe and cleavage
confirmed, while the negative control shows no processing. ‘ * ‘ Indicates the expected cleavage product of the probes (46 nt).
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amount of those miRNAs (Supplementary Fig. 1b). These data
demonstrated that EV-derived miR-451a complexes are capable
of sequence-specific target gene degradation upon 30-UTR
association. To directly demonstrate physical interaction of Ago2
and miRNA in a complex in purified EVs, we performed
immunoprecipitation with Ago2 antibodies (or an IgG isotype
control). Quantitative real-time PCR (qRT-PCR) confirmed
association of Ago2 with miR-451a (Fig. 4g), as well as with other
miRNAs detected in EVs by our Nanostring analysis
(Supplementary Fig. 1c). Furthermore mature miR-451a was
detected by Northern blot only after immunoprecipitation with
the Ago2 antibody, whereas it was not detectable in the isotype
control immunoprecipitate (Fig. 4h). Cleavage assays using a
radio-labelled miR-451a probe demonstrated functionality of the
purified miR-451a–Ago2 complex (Fig. 4i). In summary, these
results demonstrate that miRNAs in EVs are functional and
require Ago2 association for activity.
EVs from iRBCs are internalized by endothelial cells via
endocytosis. Having established the presence of functional
miRNA-Ago2 complexes in EVs, we wanted to determine their
potential physiological role during malaria infection. We have
previously shown EV internalization by iRBCs and macro-
phages11. To test whether EVs are internalized by endothelial cells
and possibly contribute to the observed changes of endothelial
function during malaria infection, we labelled purified EV
preparations with a membrane dye and co-incubated them with
a semi-immortalized human bone marrow-derived endothelial
cell line (BMEC)30. We observed increasing uptake of labelled
EVs over time, and confocal microscopy analysis demonstrated
accumulation of labelled EVs in a perinuclear region in
endothelial cells (Fig. 5a). Most experimental evidence suggests
that EVs from various cell types are internalized into the cell via
endocytosis31. Previous experiments in our laboratory and by
Regev-Rudzki et al. have demonstrated that EV internalization by
macrophages and by iRBCs is sensitive to the actin filament
inhibitor Cytochalasin D (refs 10,11). To test whether uptake of
EVs from iRBCs into BMEC is via an endocytic pathway,
we co-incubated endothelial cells either with EVs alone or
together with a series of known endocytosis inhibitors that have
previously been shown to block EV uptake31, and measured
uptake over time. Specifically we tested the actin filament
inhibitors Latrunculin A and Cytochalasin D, the microtubule
inhibitors Nocodazole and Colchicine as well the Dynamin-2
inhibitor Dynasore32. Actin filament and microtubule inhibitors
are known to block endocytosis33,34. Dynamin-2 is required both
for Clathrin-mediated and Caveolin-dependent endocytosis and
its inhibition through Dynasore can block EV uptake in other
systems35. Except for Colchicine, all compounds had a significant
effect on EV uptake (Fig. 5b), strongly suggesting that EV
internalization by endothelial cells is indeed via endocytosis.
Similar to EV-mediated activation of macrophages11, we
observed that EVs are able to induce pro-inflammatory
cytokines such as interleukin-6 (IL-6) and interleukin-1 (IL-1)
(Fig. 5c). Induction of these cytokines is known to impair
endothelial barrier function36 and increase expression of adhesion
molecules37 thereby contributing to vascular dysfunction by
inducing excessive leukocyte adhesion and transmigration. In
addition, EV internalization directly induces expression of surface
receptor vascular cell adhesion protein 1 (VCAM-1) possibly
exacerbating vascular dysfunction (Fig. 5c).
EV-derived miRNA accumulates in endothelial cells. Given the
efficient uptake and perinuclear localization of EVs in endothelial
cells, we hypothesized that they may deliver regulatory miRNAs
to the endothelial cell. For the following experiments we focused
on miR-451a because this is the most abundant miRNA species in
EVs, and its expression is restricted to cells of the erythropoietic
lineage, while not being expressed in other cell types including
endothelial cells38,39. First we determined miR-451a levels in
endothelial cells by qRT-PCR upon EV internalization,
demonstrating dose-dependent miRNA accumulation of up to
50-fold above background (Fig. 6a). Detection of miRNA in
BMEC is resistant to RNAse 1 and trypsin treatment,
demonstrating that the detected miR-451a signal originates
from internalized EVs rather than from contaminating serum
components or EVs on the BMEC surface (Fig. 6b). We were also
able to directly detect and quantify miR-451a copy number in
endothelial cells upon EV uptake by RNA fluorescent in situ
hybridization, while a scrambled probe or endothelial cells
without added EVs show only background signal (Fig. 6c).
To exclude the possibility that miR-451a expression is induced
in endothelial cells upon EV uptake, rather than transferred with
EVs, we treated BMEC with a-amanitin before incubation with
EVs. miRNAs are transcribed by RNA polymerase II, which can
be efficiently inhibited by the fungal metabolite a-amanitin40. The
increase in miR-451a expression upon EV treatment was not
affected by a-amanitin, whereas levels of the endogenous control
miRNA miR-126 remained constant (Fig. 6d). In contrast
induced expression of VCAM-1 upon EV uptake was inhibited
by a-amanitin. Altogether these experiments demonstrate that
miR-451a is transferred to endothelial cells via EVs, rather than
expressed in endothelial cells.
EVs alter gene expression and barrier properties in endothelial
cells. Next we tested whether internalized EVs can target
endothelial gene expression through RNA interference of
EV-derived miRNA complexes on target genes. miR-451a target
gene prediction using available search tools (Targetscan,
MicroSom, Microrna, DIANA lab) suggested multiple possible
targets (Supplementary Table 1), either within coding regions of
genes (that is, with a 100% match for endonucleolytic cleavage) or
within the 30-UTR of genes (that is, with a partial match for
subsequent mRNA degradation). We confirmed expression of a
subset of these putative targets in the BMEC line by microarray
expression analysis41(Fig. 7a). To evaluate possible expression
regulation by EV-derived miRNAs in BMEC, we focused on the
four previously validated miR-451a targets, CAV-1 (refs 42,43),
ATF2 (ref. 44), GRSF1 (ref. 45) and PSMB8 (ref. 46), all of which
are expressed above the median of all genes in this BMEC line
(Fig. 7a). Specifically, we quantified transcript levels by qRT-PCR
in endothelial cells upon EV incubation compared with control.
Indeed 2 markers, CAV-1 and ATF2, both with partial miR-451a
target sites in their 30-UTR (Supplementary Fig. 2), showed
significant downregulation after 24 h of EV incubation compared
with untreated control cells (Fig. 7b,c) and similar in magnitude
to a-aminitin treatment (Supplementary Fig. 3). In contrast
GRSF1 (Fig. 7d) and PSMB8 (Fig. 7e) were not affected.
CAV-1 encodes Caveolin-1, a scaffolding protein and main
component of caveolae, specialized lipid rafts in the plasma
membrane of many vertebrate cell types with a role in signal
transduction and endocytosis47. ATF2 encodes Activating
Transcription Factor 2, a multifunctional transcription factor
present in various cell types including endothelial cells48. Western
blot analysis demonstrated that both CAV-1 and ATF2 were also
downregulated on a protein level after incubation with EVs
(Fig. 7f).
As CAV-1 is known to regulate expression of proteins required
for barrier function in the microvascular endothelium49,50
we wanted to test whether EV uptake showed altered barrier
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function compared with control cells. For this purpose, we
investigated the integrity of the endothelial barrier using an
in vitro permeability assay. In this assay, we measured the effect
of EV uptake on traversing of rhodamine-labelled dextran
diffusion through BMEC monolayers grown on 0.4 mm
trans-wells filters. This experiment demonstrated dose- and
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Figure 5 | Uptake of EVs by endothelial cells. (a) Dynamics of EV internalization. Bone marrow endothelial cells (BMEC) were incubated with 100 mg of
PKH26 fluorescently labelled EVs for 0, 2, 6 or 12 h. BMECs were stained for actin (phalloidin, green) and nuclei (TO-PRO-3, blue). (i) Following washing,
the majority of internalized EVs were detected in a perinuclear region of the endothelial cell starting at 2 h post incubation. Scale bar, 10 mm. (ii) Orthogonal
views of a representative cell after 12 h of EV uptake demonstrate that EVs are internalized. Scale bar, 7 mm. (iii) Internalized EVs were quantified by means
of fluorescence intensity. Background signal was subtracted for every single image before obtaining the relative fluorescence per field. At least 15 images
were collected per condition (mean ± s.e.m.; n¼ 3 experiments). P versus control (Student’s t-test). (b) Effect of inhibitors on EV uptake. Cells were
co-incubated with inhibitors and EVs, uptake was quantified compared with control as in a. (i) Effect of known EV uptake inhibitors. Compounds were
co-incubated for 2 h with EVs and the effect measured as mean number of EVs per cell. Ctl: control. Col: Colchicine (31 nM). CytD: Cytochalasin (600nM).
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control (Student’s t-test). (c) Activation of cytokines and cell surface receptors upon EV uptake. Detection of IL-1, IL-6 and VCAM-1 by qRT-PCR in BMEC
upon incubation with an increasing amount of EVs. qRT-PCR results are normalized by the 2-Ct method, using EF-1 as a reference and expressed as mean
and fold induction over control (mean ± s.e.m.; n¼ 3 experiments), P versus control (Student’s t-test).
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time-dependent permeability increase upon EV incubation
compared with untreated control cells (Fig. 7g). In summary,
these experiments provided the first evidence of a link between
EV uptake and altered endothelial function via changes in
miR-451a target gene expression.
miR-451a alters endothelial cell function. To ascertain that
CAV-1 and ATF2 downregulation is indeed mediated by EV-
derived miR-451a, we used two complementary approaches to
directly alter miR-451a expression in BMEC and measure the
effect on target gene expression. First we transduced BMEC with
a lentiviral expression vector containing miR-451a (or GFP
control). In the resulting BMEC/miR-451a line miR-451a was
greatly induced while CAV-1 and ATF2 expression was reduced
both on transcript and protein level, when compared with the
GFP control (BMEC/GFP) and BMEC (Fig. 8a,b). In a second
experiment, we transiently expressed Sponge miR-451a in endo-
thelial cells before incubation with EVs. Sponge miRNA binds
and sequesters cellular target miRNAs and thereby neutralizes
them. Indeed expression of Sponge miR-451a but not of a control
Sponge miRNA restored CAV-1 and ATF2 expression on mRNA
and protein levels, confirming that they are genuine targets of
EV-derived miR-451a (Fig. 8d). Furthermore the overexpression
of a miR-451a sponge preserved the permeability of the
endothelial cell barrier properties upon EV treatment (Fig. 8e).
Together these experiments directly demonstrate that CAV-1 and
ATF2 are miR-451a targets. Importantly, we were also able to
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Figure 6 | Accumulation of miRNA in BMEC upon EV uptake. (a) Detection of miRNA by qRT-PCR. miR-451a was quantified by qRT-PCR in BMEC upon
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recapitulate the observed effect of EVs on endothelial barrier
properties in the BMEC/miR-451a line but not in the BMEC/GFP
control by permeability assays measuring rhodamine-labelled
dextran accumulation (Fig. 8f). Growth curves indicated a
significant reduction in trans-endothelial electrical resistance in
BMEC/miR-451a compared with BMEC/GFP (Fig. 8g), further
confirming the role of miR-451a in regulation of endothelial
barrier formation. In addition, miscoscopy experiments
performed 36 h after cell plating showed decreased levels of
cortical actin, increased stress fibre formation, discontinuous
junctional VE-Cadherin and presence of gaps between cells in the
BMEC/miR-451a cell line compared with BMEC, demonstrating
that induction of miR-451a leads to vascular alteration (Fig. 8h).
Of note, BMEC/miR-451a cells do not seem to reach overall
confluence (intact monolayer) at any time point. Altogether these
experiments confirmed a regulatory function for EV-derived
miRNA-complexes in endothelial gene expression and barrier
function.
Discussion
We have recently demonstrated that EVs derived from iRBCs are
transferred between iRBCs and capable of promoting the switch
to formation of transmission stages11. We have also demonstrated
that they are efficiently internalized by macrophages and induce a
strong inflammatory response11. Here we show that EVs derived
from iRBCs contain host miRNAs, derived from the mature
RBCs, which form a functional RISC complex with Ago2.
Importantly we show that this RISC complex is capable of
specifically silencing gene expression in endothelial cells and alter
their barrier properties. Altogether, these findings provide a
mechanistic link between malaria infection and vascular
dysfunction.
In our previous study, we demonstrated that EVs derived from
iRBCs contain small RNA species11, in line with observations of
EV-mediated transfer of RNA including miRNA in many
eukaryotic cell types51,52. Profiling of human miRNA species
revealed presence of a small set of miRNAs in EVs, with
miR-451a and let-7b having the highest expression level. These
two miRNAs are abundant in cells of the eyrthroid lineage
including mature RBCs23. miRNAs are also present in human
serum in a stable complex with lipids17,29. For example, miR-223
can form a complex with high-density lipoprotein, and this
complex is efficiently transferred to co-cultured hepatocytes
where it regulates transcription of miR-223 target genes17.
Mature RBCs, or normocytes, are terminally differentiated cells
without nucleus and organelles. Erythropoiesis is a complex
process during which hematopoietic stem cells undergo a series of
differentiation steps and ultimately enucleate to give rise to
reticulocytes, which are released from bone marrow into
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Figure 7 | Downregulation of miR-451a target genes in endothelial cells upon EV uptake. (a) Enodogenous expression of miR-451a targets in endothelial
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mean (±s.e.m.) from 3 experiments, P versus control (Student’s t-test).
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the blood circulation and mature rapidly into the terminal
normocytes. Several miRNA species have an essential role during
erythropoiesis and RBC maturation. For example, miR-320 is
expressed in reticulocytes and essential for the downregulation of
CD71 (ref. 23). Mice deficient in miR-451a show a reduction in
haematocrit, which is caused partly by an increased susceptibility
of RBCs to oxidative damage24.
We demonstrate that RBCs progressively lose the RNA
interference machinery during their maturation, while retaining
Ago2. Specifically, we detected expression of DICER and Drosha
in erythroid cells until day 18, whereas Ago2 was still detectable
in mature RBCs. Using confocal microscopy we demonstrated
that Ago2 localizes to the cell periphery and disappears during the
late iRBC cycle. We previously described that EVs are secreted
during the later stages of parasite maturation, which coincides
with degradation of the host cell cytoskeleton, and increase of
cytoplasmic Calcium levels11. The observed dynamics of Ago2
localization in iRBCs and direct evidence for its localization in
EVs therefore strongly suggest that Ago2 is quantitatively released
by EVs. Importantly, we also demonstrate that specific miRNA
species, notably miR-451a and let-7b, are associated with Ago2 in
EVs and that this complex is active. We demonstrate both
endonucleolytic activity through cleavage of specific target
probes, and 30-UTR association and subsequent target gene
degradation in HEK293 cells incubated with EVs derived from
iRBCs. This is the first demonstration of a functional RISC
complex in mature RBCs. Recent studies have demonstrated
Dicer-independent processing of miR-451a directly through Ago2
(refs 53,54), providing a possible explanation for the presence of
processed miR-451a in mature RBCs.
Multiple studies have demonstrated transfer of functional
miRNAs via EVs to target cells. Endothelial cells are targeted by
many EVs secreted by blood cells. For example miR-150 is
selectively packaged into macrophage-derived EVs and trans-
ferred to endothelial cells in which it suppresses c-Myb expression
and enhances cell migration55. Under hypoxic conditions,
myeloma cells produce exosomes containing miR-135b that
suppresses hypoxia-inducible factor 1 in endothelial cells, thereby
enhancing endothelial tube formation to control angiogenesis56.
Also, HDL-bound miR-223 suppresses ICAM-1 expression in
endothelial cells57. Our studies revealed that EVs derived from
iRBCs can regulate gene expression in the recipient endothelial
cells. Specifically, we demonstrate that EV-derived miR-451a
targets expression of the endothelial cell markers ATF2 and
CAV-1. It has previously been shown that miR-451a inhibits
ATF2 expression by binding to its 30-UTR44. ATF2 is a
cAMP-response element-binding protein with a basic leucine
zipper (bZIP) domain, through which it interacts with other bZIP
proteins44. ATF2 induces a variety of genes that are involved in
anti-apoptotic signalling58, and its inhibition by siRNA induces
apoptosis in a melanoma model59. Downregulation of ATF2 by
miR-451a might therefore contribute to the observed apoptosis of
endothelial cells during malarial infection60. The second marker
that is a target of EV-derived miR-451a in endothelial cells is
Caveolin-1 (CAV-1). CAV-1 is the principal component of
caveolae, distinct lipid- and cholesterol-rich invaginations
at the plasma membrane that function as regulators of signal
transduction. CAV-1 expression is regulated by several miRNAs,
including miR-451a (refs 42,43). CAV-1 regulates expression of
proteins required for barrier function in the microvascular
endothelium: silencing of CAV-1 by siRNA leads to reduction
of the junction-associated proteins Zona occludens protein 1
(ZO-1) and occludin expression, as well as the adherence-related
proteins VE-cadherin and b-catenin49. Similarly, CAV-1 knock-
out mice exhibit a vascular hyperpermeability phenotype61.
In line with these observations, we demonstrate that ectopic
expression of miR-451a in the BMEC line results in reduced
barrier properties and redistribution of tight junction markers.
Collectively, our data obtained through a multifaceted in vitro
approach strongly support a model where EV release contributes
both to local and systemic production of pro-inflammatory
cytokines and chemokines and to vascular dysfunction, promot-
ing endothelial activation, leakage and parasite sequestration as
well as pathology during malaria infection. Recent observations
that severe malaria is associated with a dramatic increase in EVs
in the plasma of malaria patients14 strongly support a role in vivo
for EVs in contributing to pathology. We are currently validating
this system in an in vivo model in order to determine its
implications under physiological conditions.
Methods
Plasmodium falciparum in vitro culture. Parasites of the P. falciparum reference
strain 3D7 were used for this study. Parasites were kept in fresh type 0þ human
erythrocytes (Research Blood Components, Boston, MA), suspended at 2%
hematocrit in HEPES-buffered RPMI 1640 containing 10% (w/v) heat inactivated
human serum, 0.5ml gentamycin, 2.01 g sodium bicarbonate and 0.05 g
hypoxanthine at pH 6.74. The complete medium was depleted from EVs and debris
by ultracentrifugation at 100,000g for 1 h. Cultures were kept in a controlled
environment at 37 C in a gassed chamber at 5% CO2 and 1% O2.
Isolation of extracellular vesicles. EVs from infected RBCs were isolated from
cell culture supernatants as described11. To remove cells and debris, cell
suspensions were sequentially pelleted at 600, 1,600, 3,600 and finally 10,000g for
15min each. To further concentrate the EV population, the filtrate was passed
through a Vivacell 100 filter (100 kDa molecular weight cutoff; Sartorius, Bohemia,
NY). The concentrated supernatant was then pelleted at 100,000g, the pellet
resuspended in PBS and layered on top of a 60% sucrose cushion and spun at
100,000g for 16 h. The interphase was collected and washed with PBS twice at
100,000g for 1 h.
Maturation of human RBCs from hematopoietic stem cells. Generation of
in vitro matured RBCs was conducted essentially as described previously27. Bone
marrow-derived CD34þ hematopoietic stem cells (Lonza, Switzerland) were
grown in Iscove’s Modified Dulbecco-based medium (Biochrom, Germany)
supplemented with 4mM glutamine (Sigma, St Louis, MO), 330 mgml 1
holo-transferrin (BBI solutions, UK), 10 mgml 1 insulin (Sigma), 2 IUml 1
heparin sodium salt (Affymetrix, Santa Clara, CA), Pen Strep (Thermo-Fisher,
Grand Island, NY), 100 ngml 1 stem cell factor (SCF)(R&D Systems,
Minneapolis, MN), 10 6M hydrocortisone (Sigma), 5 ngml 1 IL-3 (R&D
Systems), 3Uml 1 erythropoietin (Amgen, Cambridge, MA) and 5% pooled
solvent/detergent treated human plasma (Octaplas, Octapharma, Switzerland).
Hydrocortisone and IL-3 were removed from the culture on day 8, SCF on day 11.
Fractionation of infected red blood cells. Synchronized ring stage (12 h post
invasion) parasites were enriched to495% parasitemia by an initial Streptolysin O
treatment of 2.5 haemolytic units (HU) for 20min (ref. 62). Later stages were
enriched using magnetic separation with a MACS CS column (Miltenyi Biotec,
Cambridge, MA). Purified iRBCs were then fractionated by sequential treatment
with tetanolysin (1 HU for 20min) and saponin (0.035% for 5min).
RNA detection by Bioanalyzer, Nanostring and Northern blot. Total RNA was
isolated from EVs, iRBCs and RBCs using miRNeasy kit (Qiagen, Valencia, CA).
The concentration and integrity of total RNA was measured using a NanoDrop-
1000 spectrophotometer (Thermo Scientific, Wilmington, DE). Size distribution
was determined by Agilent 2100 Bioanalyzer with the Agilent Small RNA Chip
(Agilent Technologies, Santa Clara, CA).
For Nanostring expression analysis total RNA samples were processed
according to manufacturer’s instructions for the nCounter Human miRNA
Expression Assay kit (NanoString, Seattle, WA). Briefly, 100 ng of total RNA from
each sample was used as input for the nCounter Human miRNA preparation.
Hybridization was conducted for 16 h at 65 C. Subsequently, the strip tubes were
placed into the nCounter Prep Station for automated sample purification and
reporter capture. Abundance of specific target molecules was quantified on the
nCounter Digital Analyzer by counting the individual fluorescent barcodes and
assessing the target molecules. Data was extracted using the nCounter RCC
Collector.
To detect miRNA by northern blot 200–500 ng of total RNA per sample was
loaded onto a 15% TBE-Urea gel (Thermo-Fisher), run and transferred to a Nylon
neutral Hybond-NX membrane (GE Healthcare, Wilmington, MA) for 90min at
15V in a semi-dry electrophoretic transfer cell unit (Bio-Rad, Hercules, CA).
Membranes were ultraviolet-crosslinked. Blots were pre-hybridized at 37 C for at
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least 30min in ULTRAhyb solution (Ambion). Blots were then hybridized
overnight with a DIG labelled specific locked-nucleic acid probes (Exiqon,
Woburn, MA) for hsa-miR-451a, hsa-miR-106b and let-7b, at a final concentration
of 0.5 nM in ULTRAhyp at 37 C. Chemiluminescence detection was performed
following incubation with a horseradish peroxidase-conjugated antibody against
DIG. Northern blots were performed using RNAs from three separate experiments.
Western blot and immunofluorescence analysis (IFA). Samples were collected
and purified as described in each specific experiment. For SDS–polyacrylamide gel
electrophoresis the pellet was washed three times in PBS and taken up in reducing
SDS sample buffer (Invitrogen, Carlsbad, CA). Proteins were separated on 4–12%
Bis-Tris gels (Invitrogen) and proteins transferred onto Immun-Blot PVDF
membranes (Biorad), according to standard protocols. Antibodies used are
anti-Ago2/EIF2C2 (clone 2E12-1C9, Abnova), anti-Dicer1 (clone 13D6, Abcam),
anti-Drosha (Abcam), anti-stomatin (clone M-14; Santa Cruz Biotechnologies)
and anti-Histone H3 (Abcam). Secondary antibodies (IR-Dye-conjugated) were
goat anti-rabbit and goat anti-mouse immunoglobulin (LICOR, Lincoln, NE).
Immunoreactive bands were detected using the Odyssey imaging system (LICOR).
For IFA, iRBCs and RBCs were fixed in 4% paraformaldehyde and 0.0075%
glutaraldehyde for 30min. Cells were incubated with anti-Ago2/EIF2C2 (clone
2E12-1C9, Abnova) 1:50 for 2 h followed by Alexa Fluor 488 secondary IgG
antibodies (1:1,000; Molecular Probes, Eugene, OR) for 1 h. Nuclei were labelled
with DAPI nuclear stain (Roche) at 0.2mgml in Vectashield mounting solution
(Vector Labs, Burlingame, CA). Imaging was performed on an Olympus BX62
microscope fitted with a cooled Hamamatsu Orca AG camera. The microscope,
filters, and camera were controlled using iVision version 4.0.9 software (BioVision,
Milpitas, CA).
For flow cytometry, iRBCs and RBCs were fixed in 4% paraformaldehyde and
0.0075% glutaraldehyde for 30min. Cells were incubated with anti-Ago2/EIF2C2
(clone 2E12-1C9, Abnova) 1:50 for 2 h followed by Alexa Fluor 594 secondary IgG
antibodies (1:1,000; Molecular Probes) for 1 h. Nuclei were labelled with Sybr
Green (Life Technologies, Carlsbad, CA).
Cytometry data were collected with a MACSQuant VYB flow cytometer.
Immuno electron microscopy of EVs. Purified EVs from P. falciparum cultures
cells were fixed with 4% paraformaldehyde in 0.1 M sodium phosphate buffer at
pH 7.4 for 2 h at room temperature. Before freezing in liquid nitrogen cell pellets
were infiltrated with 2.3M sucrose in PBS containing 0.2M glycine for 15min.
Frozen samples were sectioned at  120 C and 60–80 nm sections were
transferred to formvar-carbon coated copper grids. Gold labelling was carried out
at room temperature on a piece of para film. For Ago2 labelling, antibodies were
diluted in 1% bovine serum albumin (BSA) in PBS. Grids were floated on drops of
1% BSA for 10min to block for unspecific labelling, transferred to 5 ml drops of
anti-Ago2 gold 10 nm for 30min, then washed in four drops of PBS and six drops
of double distilled water. The sections were contrasted and embedded by floating
the grids on a mixture of 0.3% uranyl acetete in 2% methyl cellulose for 5min.
Excess liquid was blotted off on a filter paper and the grids were examined in a
JEOL 1200EX Transmission electron microscope (JEOL, Peabody, MA) and images
were recorded with an AMT 2k charge-coupled device camera (AMT Woburn,
MA).
Size exclusion chromatography. Experiments to determine possible presence of
serum-derived Ago2-miRNA complexes were performed essentially as described by
Arroyo et al.29
Briefly, sephacryl S-500 resin (GE Healthcare) was packed in a chromatography
column (0.9 ÅB 30 cm, 19.1ml bed volume). Before injection, the column was
equilibrated with 25ml of PBS solution at 0.5mlmin 1 at room temperature. The
column was injected with 0.5ml of undiluted fresh serum or purified EVs and
eluted at 4 C forB1 h with PBS solution (pH 7.4) at a flow rate of 0.5mlmin 1.
A total of 25 fractions of 1ml each were collected. Fractions were stored at 4 C
before use. Protein molecular weight standards included BSA (67 kDa; GE
Healthcare) and tyrosine (0.181 kDa; Sigma-Aldrich).
Proteinase K Treatment of purified EVs. Recombinant, PCR-grade,
DNase/RNase-free proteinase K (Roche, Switzerland) was prepared in RNase-free
water. Two samples of EVs were prepared on ice. At 0min, 0mgml 1 or
5mgml 1 proteinase K was added to the plasma, and aliquots were immediately
removed and denatured in five volumes of QIAzol. The remainder of each sample
was incubated at 55 C. Aliquots were removed at time points indicated and
denatured in QIAzol.
Caenorhabditis elegans spike-in oligonucleotides were added to denatured
samples, and the samples were stored at  80 C as they were generated. RNA was
isolated as described above. Samples were also taken for SDS–polyacrylamide gel
electrophoresis and western blot analysis.
RISC assays. RISC assays were essentially performed as previously described63.
Sensor RNA transcripts harbouring binding sites complementary to endogenous
miRNAs hsa-miR-451a or hsa-let-7b were prepared by in vitro transcription using
T7 RNA promoter/polymerase (T7 MEGAshortscript kit, Ambion). DNA
templates were prepared by annealing of two complementary oligonucleotides.
After gel purification, the RNA sensors were dephosphorylated with calf intestine
alkaline phosphatase (Roche), 50-end labelled with [g-32P] ATP (Perkin-Elmer)
using 10U opti-kinase (USB). For activity assays we prepared protein extracts from
EVs in S100 lysis buffer (40mM Hepes, 100mM potassium acetate, 5mM MgCl2,
2mM DTT, 0.35% (v/v) Triton X-100, pH 7.6). We incubated 50 mg of S100
protein extracts or Ago2 immunoprecipitates with the 32P-labelled RNA sensor
(10,000 c.p.m.) in assay buffer containing 20mM Hepes, 50mM potassium acetate,
2.5mM MgCl2, 1mM ATP, 0.2mM GTP, 1mM DTT, 2.5% (v/v) Superase-In,
0.18% (v/v) Triton X-100, pH 7.6, at 30 C for 90min. Some experiments were
performed with pre-incubation in the presence of proteinase K (1mgml 1) or
EDTA (5mM). The latter reaction was stopped by adding 0.5mgml 1 of
proteinase K and incubation at 50 C for 30min. After a phenol/chloroform
extraction step, the RNA products were precipitated, resuspended in water,
separated by 10% polyacrylamide gel electrophoresis in 7M urea
(Life Technologies) and analysed by autoradiography.
Reporter gene activity assays. Reporter gene activity assays were performed
essentially as described previously64. A miR-451a reporter construct was created by
inserting a sequence complementary to hsa-miR-451 into the Xho I and Not I sites
of psiCHECK-2 vector (Promega, Madison, WI), downstream of the Renilla
luciferase (Rluc) reporter gene. Firefly luciferase (Fluc) was used as a normalization
control. Constructs were transfected into HEK293 cells 24 h before incubation with
EVs for up to 48 h. Rluc and Fluc activities were measured with Dual Glo-luciferase
reagents (Promega) using a luminometer (Dynex Technologies, Chantilly, VA).
Immunoprecipitation (IP) of Ago2-microRNA complexes. EVs derived from
iRBCs were lysed in RNA IP lysis buffer (20mM Tris-HCl pH 7.5, 150mM NaCl,
1.5mM MgCl2, and 0.25% NP-40), and the lysates cleared by centrifugation before
IP using protein G-agarose beads (Roche) conjugated to an anti-Ago2 antibody
(clone 2E12-1C9, Abnova) or isotypic IgG control (Novus), as described pre-
viously63. Ago2-associated miR-451a and let-7b was isolated by phenol/chloroform
extraction and ethanol precipitation, reverse transcribed with the TaqMan
MicroRNA reverse Transcription Kit (Applied Biosystems, Foster City, CA), and
analysed by qRT-PCR using hsa-miR-451a or let-7b TaqMan Small RNA Assays
(Applied Biosystems). The Ago2-miR-451a function was then evaluated in RISC
activity assays, as previously described in the RISC activity section.
Endothelial cell culture. A semi-immortalized human BMEC-1 (ref. 30) was
cultured in DMEM (Life technologies) supplemented with 10% fetal bovine serum
(Cedarlane, Burlington, Canada) and maintained at 37 C under 5% CO2.
miRNA Target predictions. The mature miR-451a sequence was obtained from
miRBase (http://www.mirbase.org). The human targets of HSA-miR451a were
predicted using public Web-based prediction tools, including TargetScan (http://
www.targetscan.org), MicroCosm (http://www.ebi.ac.uk/enright-srv/microcosm),
microRNA.org (http://www.microrna.org/microrna/getGeneForm.do) and Diana
LAB (http://diana.cslab.ece.ntua.gr/micro-CDS).
RNA extraction and gene expression studies in BMEC-1. Total RNA was
extracted from iRBC-derived EVs and BMEC-1 using TRIzol reagent (Invitrogen),
and from the supernatant fraction using miRVana PARIS kit (Ambion). Reverse
transcription reactions were performed with 1 mg total RNA using HiFlex
miSCRIPT RTII kit (Qiagen) after DNase I treatment (Invitrogen). Mature
miR-451a and selected mRNAs were detected by qRT-PCR using miScript
Primer Assay kit and SYBR Green (Qiagen). Small nuclear RNA U6 (RNU6)
(for miR-451a) and 18 S rRNA and EF1 (for mRNAs) were used as reference genes
for relative quantitation using the 2Ct method.
EV internalization assays with BMEC-1 and miRNA transduction. Purified EVs
were labelled with PKH26 red fluorescent labelling kit (Sigma-Aldrich) and
incubated with BMECs for 2, 6 or 12 h before washing cells three times to
remove unbound EVs. For uptake inhibition experiments endothelial cells were
co-incubated with different compounds, as described in Fig. 5. Cells were fixed,
permeabilized and stained for F-actin with phalloidin-Alexa-Fluor-488
(Invitrogen) and with the nuclear dye Topro-3 (Thermo-Fisher). Epifluorescence
was performed on a Axiovert 200M microscope (Carl Zeiss. Germany) equipped
with a camera (Orca charge-coupled device; Hamamatsu Photonics, Japan) using a
 40 Plan-Neofluar (NA 1.3) oil immersion objective. Intensity analysis was
performed with the Axiovision 4.6.3 software. Background subtraction was
performed for each field. Confocal microscopy was performed on a Zeiss LSM
510 Laser Scanning Microscope using a  63 Plan-Neofluar water-immersion
objective.
RNA Fluorescence in situ hybridization. We performed RNA fluorescent in situ
hybridization staining essentially as described65, using 10 nM of DIG-labelled
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miRNA LNA probes (Exiqon). A scrambled miRNA LNA probe was used as a
negative control. After a series of post-hybridization washes, the LNA signal
was amplified using the Tyramide Signal Amplification PLUS Fluorescein Kit
(Perkin-Elmer, Waltham MA) according to the manufacturer’s instructions.
Generation of BMEC/miR-451a and BMEC/GFP lines. For the construction of
the miR-451a lentiviral vector, fragments containing the human miR-451a genomic
clusters were amplified by PCR from human genomic DNA and directionally
cloned into the AgeI and EcoRI sites of the pLKO-1 vector (Addgene, Cambridge,
MA) using the primers: forward 50-AAAAACCGGTCTAGTCCGGGCACCCC
CAG-30 and reverse 50-AAAAGAATTCCCTACCCCCAATCCCACGC-30 .
Mission miRNA inhibitor cel-miR-243-3p (Control Sponge) and hsa-miR-451a
(Sponge) were purchased from Sigma-Aldrich.
Lentiviral particles were produced by transfecting HEK293T cells using the
calcium phosphate method with packaging plasmid psPAX2 and envelope plasmid
pMD2.G (both Addgene) and harvesting supernatants after 48 h, essentially as
described by Alves et al.66 Viral supernatant was harvested 48 h post transfection,
filtered (0.45 mm pore size), and transduced into BMEC cells in the presence of
8 mgml 1 of polybrene (Sigma-Aldrich). After 24 h, cells were maintained in
medium containing 0.6 mgml 1 puromycin (Sigma-Aldrich) for selection.
IFAs with wild-type and transduced BMEC lines. To investigate barrier function
control BMECs and the transduced BMEC/miR-451a cell line were grown to
confluence for 36 h before fixation, staining for VE-cadherin followed by
AlexaFluor-conjugated secondary antibody, permeabilization and staining for
phalloidin-Alexa-Fluor-488 to detect F-actin and DAPI to detect nuclei. Cells were
analysed by epifluorescence as above.
Permeability and TEER assays. The permeability of treated BMEC monolayers
grown on transwell filters (0.4 mm pore size; Corning, Durham, NC) was assessed
by the passage of rhodamine B isothiocyanate-dextran (average MW B70,000;
Sigma). Briefly, rhodamine-dextran was added to the top well at 20mgml 1, and
the appearance of fluorescence in the bottom well was monitored by measuring
40ml medium aliquots in a time course using a multilabel microplate reader
(Perkin-Elmer) at 544 nm excitation and 590 nm emission. The cells were
incubated at 37 C with 5% CO2.
For trans-endothelial electrical resistance assays endothelial cells were plated on
gold-coated electrodes (40,000 cells per well) and trans-endothelial electrical
resistance was monitored in real time by electric cell-substrate impedance sensing
(Applied BioPhysics), as previously described67. Resistance (O) values were
analysed by normalizing against baseline levels.
Data availability. All relevant data are available from the authors. Also please note
that all western blots shown in the manuscript have been cropped but full,
uncropped blots are available in Supplementary Figs 4–6.
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